Optimal first-line treatment for metastatic ALK+ non-small cell lung cancer-a narrative review.

ABSTRACT:

Background and objective

First-line treatment options for patients with advanced non-small cell lung cancer (aNSCLC) whose tumors harbour anaplastic lymphoma kinase (ALK) gene rearrangements have rapidly evolved from chemotherapy, to the first in class ALK-targeted tyrosine kinase inhibitor (TKI) crizotinib in 2011, and now include no fewer than five Food and Drug Administration (FDA)-approved ALK inhibitors. However, while superiority to crizotinib has been established, head-to-head clinical trials comparing newer generation ALK inhibitors are lacking, and decisions on optimal first-line treatment must be based on analysis of the relevant trials, with attention to systemic and intracranial efficacy, toxicity profile as well as consideration of patient factors and preference

SUBMITTER: Chazan G 

PROVIDER: S-EPMC9989801 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature